Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment
Status: | Recruiting |
---|---|
Conditions: | Breast Cancer, Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/20/2019 |
Start Date: | November 29, 2016 |
End Date: | May 31, 2019 |
Contact: | Steven Poplack, M.D. |
Email: | poplack@wustl.edu |
Phone: | 314-454-7405 |
To determine the accuracy of NIR/US assessment of tumor vasculature and oxygen changes in
predicting and monitoring early neoadjuvant treatment response compared to pathological
response.
predicting and monitoring early neoadjuvant treatment response compared to pathological
response.
Inclusion Criteria:
- Scheduled to receive neoadjuvant chemotherapy for the treatment of newly diagnosed,
locally advanced breast cancer or scheduled to receive neoadjuvant endocrine therapy
with the eventual goal of surgery of newly diagnosed clinical stage II-III ER+ HER2-
breast cancer (for the endocrine therapy cohort)
- At least 18 years of age
- Female
- Able to understand and willing to sign an IRB-approved written informed consent
document
Exclusion Criteria:
- Pregnant and/or breastfeeding
- Prior history of breast cancer
- Prior history of chest wall radiation
- Prior history of breast reconstruction, reduction, or augmentation
We found this trial at
1
site
660 S Euclid Ave
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Steven Poplack, M.D.
Phone: 314-454-7405
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Click here to add this to my saved trials